Schrödinger, Inc. (SDGR) AI Stock Analysis

Schrödinger, Inc. provides a physics-based computational software platform for novel molecule discovery in drug development and materials science. Established in 1990 and headquartered in New York, the company operates across two segments: Software and Drug Discovery. The Software segment licenses computational tools to support molecular simulation and discovery across life sciences and materials science. The Drug Discovery segment develops an internal and collaborative portfolio of preclinical and clinical therapeutic candidates. Its customer base includes biopharmaceutical firms, industrial companies, academic institutions, and government laboratories across the world.

Revenue increased from $137.9M in FY2021 to $255.9M in FY2025, representing a 5-year revenue CAGR of 18.8%. Annual revenue grew 23.3% in FY2025 after a decline of 4.2% in FY2024. Gross margin stood at 55.7% in FY2025, while operating margin was -65.2% and net income was -$103.3M. R&D expenses were $173.1M in FY2025, down from $201.8M in FY2024. For the trailing twelve months ending June 30, 2026, revenue reached $259.0M with an operating margin of -70.5% and diluted EPS of -$0.74. In the latest quarter ending June 30, 2026, quarterly revenue grew 7.5% year-over-year.

As of June 30, 2026, Schrödinger held $413.7M in cash and short-term investments and $108.0M in total debt, resulting in net cash of $305.8M. Total assets stood at $640.4M against shareholders' equity of $329.0M, supporting a current ratio of 2.71 and a debt-to-equity ratio of 0.33. Operating cash flow improved to $13.9M in FY2025, while free cash flow reached $12.5M alongside $1.4M in capital expenditures. Share count increased 7.0% over five years.

At a last close of $22.60 on October 16, 2026, Schrödinger trades at an enterprise value of $1.88B and a price-to-sales multiple of 6.5x, above the 4.1x median of its US-listed Healthcare peers. Its enterprise value-to-revenue multiple is 7.3x, and price-to-book is 6.6x. The stock returned 11.3% over the past year and -59.2% over five years, trailing the S&P 500 (SPY) returns of 16.8% and 83.0% over those respective periods. Shares trade 37.8% above their 200-day moving average with a beta of 1.62.

Wall Street analysts hold 5 Strong Buy and 2 Hold ratings on Schrödinger. The mean price target is $25.57, representing a 13.1% premium to the last close of $22.60. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $241.5M and an EPS of -$1.64. For the following fiscal year, 5 analysts expect revenue of $248.9M and an EPS of -$1.38. Schrödinger beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Schrödinger, Inc. (SDGR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SDGR income statement, SDGR balance sheet, SDGR key metrics, SDGR analyst forecast, SDGR chart. See the SDGR stock overview for the latest quote and news.